Sartorius to advance drug discovery and manufacturing with AI in
collaboration with NVIDIA

EQS-News: SARTORIUS AG / Key word(s): Alliance
Sartorius to advance drug discovery and manufacturing with AI in
collaboration with NVIDIA (news with additional features)

16.05.2024 / 09:54 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Göttingen, Germany, May 16, 2024
Sartorius to advance drug discovery and manufacturing with AI in
collaboration with NVIDIA

  * Exploring advanced technologies to help bring novel therapies to
    patients faster

  * Sartorius to leverage NVIDIA solutions used in live-cell imaging
    platforms in drug discovery, and predictive design of manufacturing
    processes, and more

  * Future plans include the creation of foundational models based on
    Sartorius' extensive and unique data sets, as well as new predictive AI
    models, tools, and simulations

  * Dialogue with regulatory authorities on the use of AI in life sciences
    announced

The life science group Sartorius is expanding its multidisciplinary
collaboration with NVIDIA to help enable the development of new and better
therapies, combining Sartorius' in-depth knowledge of life sciences and
bioprocessing with NVIDIA's AI-powered computing platforms and software.

"Biological interactions are exceptionally complex. Making better use of
data by integrating life science expertise with AI solutions is a promising
approach to simplify and accelerate biopharma drug discovery and
manufacturing progress. This expanded collaboration with NVIDIA will help
result in relevant technological innovations for our customers and
ultimately for patients," said Prof. Dr. Oscar-Werner Reif, Chief Technology
Officer of Sartorius.

Sartorius has been working with NVIDIA since 2020. The life science group
has integrated NVIDIA's technology into its instruments, enabling edge
computing applications of its live-cell imaging platform for commercialized
AI assays in the lab. The focus of the collaboration has been on developing
predictive AI models of stem cell-derived organoids to replace animal models
in drug discovery and precision medicine. Sartorius is also using NVIDIA
solutions for predictive bioprocess design and simulation tools for
manufacturing innovative therapies.

The expanded collaboration includes increasing adoption of the NVIDIA Clara
suite of AI-powered computing platforms, software, and services in the
Sartorius ecosystem. Plans involve creating and commercializing powerful
foundational models based on Sartorius' extensive and unique data sets. New
predictive AI models, tools, and simulations for numerous application areas
will also be available to Sartorius customers through the NVIDIA Clara suite
and the NVIDIA DGX platform.

In a forward-looking approach to innovation and technology integration in
the biopharmaceutical sector, the collaboration will explore numerous
advanced technologies, including the computer-based design and simulation of
complex 3D-bioprinted spheroids and organoids or synthetic biological
pathways and organisms designed based on Sartorius cell lines, to produce
novel therapeutic agents and therapies.

A profile of Sartorius
Sartorius (XETRA: SRT3 | SRT) is a leading international partner of life
sciences research and biopharmaceutical manufacturing. With innovative
laboratory instruments and consumables, the Group's Lab Products & Services
division focuses on laboratories performing research and quality control at
pharmaceutical and biopharmaceutical companies as well as academic research
institutes. The Bioprocess Solutions division, with its broad product
portfolio focusing on single-use solutions, helps customers manufacture
biotech medications, vaccines, and cell and gene therapies safely, rapidly,
and economically. The company, based in Göttingen, Germany, has a strong
global reach with around 60 production and sales sites worldwide. Sartorius
regularly expands its portfolio through the acquisition of complementary
technologies. In 2023, the company generated sales revenue of around 3.4
billion euros. Currently, around 14,600 employees are working for customers
around the globe.

Visit our Newsroom or follow us on LinkedIn.


Contact
Leona Malorny
Head of External Communications
+49 551 308 4067
leona.malorny@sartorius.com


---------------------------------------------------------------------------

Additional features:

File: https://eqs-cockpit.com/c/fncls.ssp?u=7ee947715ca1c98545f993dbbadec5b0
File description: 2024-05-16_Sartorius_Media Release_NVIDIA_Collaboration_en

---------------------------------------------------------------------------

16.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        SARTORIUS AG
                   Otto-Brenner-Straße 20
                   37079 Göttingen
                   Germany
   Phone:          +49.(0)551-308.0
   Fax:            +49.(0)551-308.3289
   E-mail:         info@sartorius.com
   Internet:       www.sartorius.com
   ISIN:           DE0007165607, DE0007165631
   WKN:            716560 , 716563
   Indices:        DAX, TecDAX
   Listed:         Regulated Market in Frankfurt (Prime Standard),
                   Hanover; Regulated Unofficial Market in Berlin,
                   Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate
                   Exchange
   EQS News ID:    1904837

End of News EQS News Service
---------------------------------------------------------------------------

1904837 16.05.2024 CET/CEST